0.6055  0.053 (9.63%)		02-27 16:00
Open: 0.581 High: 0.65 Volume: 822,480		Pre. Close: 0.5523 Low: 0.581 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	0.8	1-year :	0.9
Resists	First :	0.68	Second :	0.77
Pivot price	0.59
Supports	First :	0.54	Second :	0.45
MAs	MA(5) :	0.58	MA(20) :	0.6
	MA(100) :	0.83	MA(250) :	0.9
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	33.7	D(3) :	31.8
RSI	RSI(14): 45.6
52-week	High :	2.1	Low :	0.4

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ KAPA ] has closed below upper band by 38.6%. Bollinger Bands are 57.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.75 - 0.75	0.75 - 0.76
Low:	0.55 - 0.55	0.55 - 0.55
Close:	0.55 - 0.55	0.55 - 0.56

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Fri, 27 Feb 2026
KAPA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Thu, 26 Feb 2026
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal - TipRanks

Thu, 26 Feb 2026
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics - STT Info

Tue, 03 Feb 2026
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Tue, 14 Oct 2025
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO - AlphaStreet News

Tue, 07 Oct 2025
Kairos Pharma stock rises after selection for ESMO Congress presentation - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.